MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:40Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antimuscarinics]]
			[[Category:Short-acting muscarinic antagonists]]
			[[Category:Bronchodilators]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #268

2026-05-23T04:08:52Z

parser-claude batch MedTemplate pre-fill, Top 300 #268

New page

{{MedTemplate
| generic = Ipratropium bromide
| brand = Atrovent (inhaler, intranasal); also generic
| structure =
| classes = [[:Category:Antimuscarinics|Antimuscarinic]], [[:Category:Short-acting_muscarinic_antagonists|Short-acting muscarinic antagonist (SAMA)]], [[:Category:Bronchodilators|Bronchodilator]]
| uses = <vote slug="copd-exacerbation-use">COPD exacerbation (with albuterol)</vote>, <vote slug="severe-asthma-exacerbation-use">Severe asthma exacerbation (adjunct to albuterol)</vote>, <vote slug="rhinorrhea-use">Vasomotor rhinitis / rhinorrhea (intranasal)</vote>
| starting_dose = Nebulized 500 mcg q6-8h (or with albuterol as DuoNeb); MDI 17 mcg/puff, 2 puffs QID; nasal 0.03% or 0.06% spray BID-TID
| preparations = Atrovent HFA 17 mcg/actuation MDI; 500 mcg/2.5 mL nebulizer solution; 0.03% and 0.06% intranasal sprays; with albuterol as DuoNeb / Combivent Respimat
| fda_max = 12 puffs MDI/d typical; nebulized 2000 mcg/d
| pill_id =
| routes = Inhaled (MDI, nebulized), intranasal
| onset = Bronchodilation 15-30 minutes
| duration = 4-6 hours
| halflife = ~2 hours (plasma; minimal relevance — local-action drug)<ref name="atrovent-label">FDA Prescribing Information, Atrovent HFA (ipratropium bromide), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021527s019lbl.pdf</ref>
| bioavailability = Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)<ref name="atrovent-label" />
| pregnancy = Limited data; generally considered acceptable when needed.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="ipratropium-mech-claim">Ipratropium is a quaternary ammonium derivative of atropine that non-selectively antagonizes airway muscarinic receptors (M1, M2, M3), blocking acetylcholine-mediated bronchoconstriction; the charged quaternary structure prevents BBB crossing, eliminating CNS antimuscarinic effects.</vote> Slower onset than β2-agonists; primary role is as add-on to albuterol in COPD/asthma exacerbations, where the combination shows greater bronchodilation than either alone. Inhaled antimuscarinic systemic absorption is minor but can produce dry mouth, tachycardia, and (rarely) urinary retention<ref name="atrovent-label" />.
}}

== References ==
<references />

Ipratropium - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #268